bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Inclusion Criteria

• •1. Diagnosis of infiltrative HCC.
• •2. Infiltrative HCC was characterized as follows: nonencapsulated arterial phase hyperenhancement; tumor washout in the period of portal phase, and noncircular, ill-defined margin
• •3. Age between 18 and 75 years;
• •4. The maximum tumor size ≥10 cm, and the total tumor size ≥15 cm;
• •5. Infiltrative HCC, with PVTT type I or type II or limited metastases (≤5).
• •6. Child-Pugh class A or B;
• •7. Eastern Cooperative Group performance status (ECOG) score of 0-2;
• •8. Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 32 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) \>1,500/mm3
• •9. Prothrombin time ≤18s or international normalized ratio \< 1.7.
• •10. Ability to understand the protocol and to agree to and sign a written informed consent document.